DNA Damage Recognition: Toxicological and Medical Prospects

  • Hanspeter Naegeli
Part of the Molecular Biology Intelligence Unit book series (MBIU)


There is mounting evidence that knowledge about the mechanisms by which DNA damage is recognized in mammalian cells may have major impacts in toxicological and medical sciences. This chapter is intended to provide a few very different examples of currently unresolved human health-related problems (low-dose risk assessment, anticancer therapy, antiviral agents), where DNA damage recognition processes play a prominent role.


Herpes Simplex Virus Type Excision Repair Nucleotide Excision Repair Cyclobutane Pyrimidine Dimer Upstream Binding Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kat A, Thilly WG, Fang WH et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90:6424–6428.CrossRefGoogle Scholar
  2. 2.
    Branch P, Aquilina G, Bignami M et al. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993; 362:652–654.CrossRefGoogle Scholar
  3. 3.
    Klein JC, Bleeker MJ, Roelen HCPF et al. Role of nucleotide excision repair in processing of O 4-alkylthymines in human cells. J Biol Chem 1994; 269:25521–25528.Google Scholar
  4. 4.
    Hays JB, Ackerman EJ, Pang QS. Rapid and apparently error-prone excision repair of nonreplicating UV-irradiated plasmids in Xenopus laevis oocytes. Mol Cell Biol 1990; 10:3505–3511.Google Scholar
  5. 5.
    Hartwell LH. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71:543–546.CrossRefGoogle Scholar
  6. 6.
    Kuerbitz SJ, Plunkett BS, Walsh WV et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89:7491–7495.CrossRefGoogle Scholar
  7. 7.
    Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74:777–779.CrossRefGoogle Scholar
  8. 8.
    Wang XW, Vermeulen W, Coursen JD et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996; 10:1219–1232.CrossRefGoogle Scholar
  9. 9.
    Myhr BC, Turnbull D, DiPaolo JA. Ultraviolet mutagenesis of normal and xeroderma pigmentosum variant human fibroblasts. Mutat Res 1979; 63:341–353.Google Scholar
  10. 10.
    Wang YC, Maher VM, McCormick JJ. Xeroderma pigmentosum variant cells are less likely than normal cells to incorporate dAMP opposite photoproducts during replication of UV-irradiated plasmids. Proc Natl Acad Sci USA 1991; 88:7810–7814.CrossRefGoogle Scholar
  11. 11.
    Wang YC, Maher VM, Mitchell DL et al. Evidence from mutation spectra that the UV hypermutability of xeroderma pigmentosum variant cells reflects abnormal, error-prone replication on a template containing photoproducts. Mol Cell Biol 1993; 13:4276–4283.Google Scholar
  12. 12.
    Lawrence C. The RAD6 DNA repair pathway in Saccharomyces cerevisiae: what does it do, and how does it do it? BioEssays 1994; 16:253–257.CrossRefGoogle Scholar
  13. 13.
    Nelson JR, Lawrence CW, Hinkle DC. Deoxycytidyl transferase activity of yeast REV1 protein. Nature 382; 382:729-731.Google Scholar
  14. 14.
    Nelson JR, Lawrence CW, Hinkle DC. Thymine-thymine dimer bypass by yeast DNA polymerase ζ. Science 1996; 272:1646–1649.CrossRefGoogle Scholar
  15. 15.
    Würgler FE. Recombination and gene conversion. Mutat Res 1992; 284:3–14.CrossRefGoogle Scholar
  16. 16.
    Schimke RT, Sherwood SW, Hill AB et al. Overreplication and recombination of DNA in higher eukaryotes: potential consequences and biological implications. Proc Natl Acad Sci USA 1986; 83:2157–2161.CrossRefGoogle Scholar
  17. 17.
    Bohr VA, Smith CA, Okumoto DS et al. DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell 1985; 40:359–369.CrossRefGoogle Scholar
  18. 18.
    Christians FC, Hanawalt PC. Lack of transcription-coupled repair in mammalian ribosomal RNA genes. Biochemistry 1993; 32:10512–10518.CrossRefGoogle Scholar
  19. 19.
    Friedberg EC. Relationships between DNA repair and transcription. Annu Rev Biochem 1996; 65:15–42.CrossRefGoogle Scholar
  20. 20.
    Hoffmann J-S, Pillaire M-J, Maga G et al. DNA polymerase β bypasses in vitro a single d(GpG)-cisplatin adduet placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA 1995; 92:5356–5360CrossRefGoogle Scholar
  21. 21.
    Treiber DK, Zhai X, Jantzen H-M et al. Cisplatin-DNA adduets are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci USA 1994; 91:5672–5676.CrossRefGoogle Scholar
  22. 22.
    MacLeod MC, Powell KL, Tran N. Binding of the transcription factor, Spl, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis 1995; 16:975–983.CrossRefGoogle Scholar
  23. 23.
    Miller JA, Miller EC. Metabolic activation of carcinogenic aromatic amines and amides via N-hydroxylation and JV-hydroxy esterification and its relationship to ultimate carcinogens as electrophilic reactants. In: Bergmann ED, Pullman B, eds. The Jerusalem Symposia on Quantum Chemistry and Biochemistry, Physicochemical Mechanism of Carcinogenesis. Jerusalem: The Israel Academy of Sciences and Humanities, 1969:237–261.Google Scholar
  24. 24.
    Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. Cancer Res 1982; 42:4875–4917.Google Scholar
  25. 25.
    Meehan T, Straub K, Calvin M. Benzo[a]pyrene diol epoxide covalently binds to deoxyguanosine and deoxyadenosine in DNA. Nature 1977; 269:725–727.CrossRefGoogle Scholar
  26. 26.
    Mehan T, Straub K. Double-stranded DNA stereoselectively binds benzo[a]-pyrene diol epoxides. Nature 1979; 277:410–412.CrossRefGoogle Scholar
  27. 27.
    Cheng SC, Hilton BD, Roman JM et al. DNA adducts from carcinogenic and noncarcinogenic enantiomers of benzo[a] pyrene dihydrodiol epoxide. Chem Res Toxicol 1989; 2:334–340.CrossRefGoogle Scholar
  28. 28.
    Cosman M, de los Santos C, Fiala R et al. Solution conformation of the (+)-cis-anti-[BP]dG adduct in a DNA duplex: intercalation of the covalently attached benzo[a]pyrenyl ring into the helix and displacement of the modified deoxyguanosine. Biochemistry 1993; 32:4146–4155.Google Scholar
  29. 29.
    Cosman M, Hingerty BE, Luneva N et al. Solution conformation of the (-)-cis-anti-benzo[a]pyrenyl-dG adduct opposite dC in a DNA duplex: intercalation of the covalently attached BP ring into the helix with base displacement of the modified deoxyguanosine into the major groove. Biochemistry 1996; 35:9850–9863.CrossRefGoogle Scholar
  30. 30.
    Brash DE, Rudolph JA, Simon JA et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88:10124–10128.CrossRefGoogle Scholar
  31. 31.
    Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427–428.CrossRefGoogle Scholar
  32. 32.
    Bressac B, Kew M, Wands J et al. Selective G to T mutations of p 53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429–431.CrossRefGoogle Scholar
  33. 33.
    Denissenko MF, Pao A, Tang M-S et al. Preferential formation of benzo[a]-pyrene adducts at lung cancer mutational hotspots in P53. Science 1996; 274:430–432.CrossRefGoogle Scholar
  34. 34.
    Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262:1980–1981.CrossRefGoogle Scholar
  35. 35.
    Ames BN, Shinegaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90:7915–7922.CrossRefGoogle Scholar
  36. 36.
    Maher VM, McCormick JJ. Effect of DNA repair on the cytotoxicity and rautagenicity of UV irradiation and of chemical carcinogens in normal and xeroderma pigmentosum cells. In: Yuhas JM, Tennant RW, Regan JD, eds. Biology of Radiation Carcinogens. New York: Raven Press, 1976:129–145.Google Scholar
  37. 37.
    Maher VM, Ouellette LM, Curren RD et al. Frequency of ultraviolet light-induced mutations is higher in xeroderma pigmentosum variant cells than in normal human cells. Nature 1976; 261:593–595.CrossRefGoogle Scholar
  38. 38.
    Kraemer KH, Lee M-M, Andrews AD et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. Arch Dermatol 1994; 130:1018–1021.CrossRefGoogle Scholar
  39. 39.
    Nakane H, Takeuchi S, Yuba S et al. High incidence of ultraviolet-B-or chemicalcarcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene. Nature 1995; 377:165–168.CrossRefGoogle Scholar
  40. 40.
    de Vries A, van Oostrom CTM, Hofhuis FMA et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 1995; 377:169–173.CrossRefGoogle Scholar
  41. 41.
    Sands AT, Abuin A, Sanchez A et al. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 1995; 377:162–165.CrossRefGoogle Scholar
  42. 42.
    van Hoffen A, Natarajan AT, Mayne LV et al. Déficient repair of the transcribed strand of active genes in Cockayne’s syndrome cells. Nucleic Acids Res 1993; 21:5890–5895.CrossRefGoogle Scholar
  43. 43.
    Kantor GJ, Bastin SA. Repair of some active genes in Cockayne syndrome cells is at the genome overall rate. Mutat Res 1995; 336:223–233.CrossRefGoogle Scholar
  44. 44.
    Tornaletti S, Pfeifer GP. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 1994; 263:1436–1438.CrossRefGoogle Scholar
  45. 45.
    Gao S, Drouin R, Holmquist GP. DNA repair rates along the human PGK1 gene at nucleotide resolution. Science 1994; 263:1438–1440.CrossRefGoogle Scholar
  46. 46.
    Wei D, Maher VM, McCormick JJ. Site-specific rates of excision repair of benzo-[a]pyrene diol epoxide in the hypoxan-thine phosphoribosyltransferase gene of human fibroblasts: correlation with mutation spectra. Proc Natl Acad Sci USA 1995; 92:2204–2208.CrossRefGoogle Scholar
  47. 47.
    Hurley LH, Boyd FL. DNA as a target for drug action. Trends Pharmacol Sci 1988; 91:402–407.CrossRefGoogle Scholar
  48. 48.
    Wang G, Glazer PM. Altered repair of targeted psoralen photoadducts in the context of an oligonucleotide-mediated triple helix. J Biol Chem 1995; 270:22595–22601.CrossRefGoogle Scholar
  49. 49.
    Chu G. Cellular responses to cisplatin. J Biol Chem 1994; 269:787–790.Google Scholar
  50. 50.
    Bradley LJN, Yarema KJ, Lippard et al. Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum. Biochemistry 1993; 32:982–988.CrossRefGoogle Scholar
  51. 51.
    Hennings H, Shores RA, Poirier MC et al. Enhanced malignant conversion of benign mouse skin tumors by cisplatin. J Natl Cancer Inst 1990; 82:836–840.CrossRefGoogle Scholar
  52. 52.
    Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst 1992; 84:306–312.CrossRefGoogle Scholar
  53. 53.
    Hess MT, Schwitter U, Petretta M et al. DNA synthesis arrest at C4′-modified deoxyribose residues. Biochemistry 1997; in press.Google Scholar
  54. 54.
    Hess MT, Schwitter U, Petretta M et al. Site-specific DNA substrates for human excision repair: comparison between deoxyribose and base adducts. Chem Biol 1996; 3:121–128.CrossRefGoogle Scholar
  55. 55.
    Pelletier H, Sawaya MR, Kumar A et al. Structures of ternary complexes of rat DNA polymerase β, a DNA template-primer, and ddCTP. Science 1994; 264:1891–1903.CrossRefGoogle Scholar
  56. 56.
    Fawl RL, Roizman B. Induction of reactivation of herpes simplex virus in murine sensory ganglia in vivo by cadmium. J Virol 1993; 67:7025–7031.Google Scholar
  57. 57.
    Minson AC. Interactions of herpes simplex viruses with the host cell. Biochem Soc Trans 1994; 22:298–301.Google Scholar
  58. 58.
    O’Meara M, Ouvrier R. Viral encephalitis in children. Curr Opin Pediatr 1996; 8:11–15.CrossRefGoogle Scholar
  59. 59.
    Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis 1995; 20:414–420.CrossRefGoogle Scholar
  60. 60.
    Bowsher D. Post-herpetic neuralgia in older patients. Incidence and optimal treatment. Drugs Aging 1994; 5:411–418.CrossRefGoogle Scholar
  61. 61.
    Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995; 28:281–290.CrossRefGoogle Scholar
  62. 62.
    Wagstaff AF, Faulds D, Goa KL. Acyclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47:153–205.CrossRefGoogle Scholar
  63. 63.
    Coen DM. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 1994; 2:481–485.CrossRefGoogle Scholar
  64. 64.
    Pottage JC, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 1995; 4:115–124.Google Scholar
  65. 65.
    Laufer DS, Starr SE. Resistance to antivirals. Pediatr Clin North Am 1995; 42:583–599.Google Scholar
  66. 66.
    Pyles RB, Thompson RL. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J Virol 1994; 68:4963–4972.Google Scholar
  67. 67.
    Focher F, Verri A, Spadari S et al. Herpes simplex virus type 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives. Biochem J 1993; 292:883–889.Google Scholar
  68. 68.
    Mol CD, Arvai AS, Slupphaug G et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell 1995; 80:869–878.CrossRefGoogle Scholar
  69. 69.
    Sawa R, McAuley-Hecht K, Brown T et al. The structural basis of specific baseexcision repair by uracil-DNA glycosylase. Nature 1995; 373:487–493.CrossRefGoogle Scholar
  70. 70.
    Mol CD, Arvai AS, Sanderson RJ et al. Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA. Cell 1995; 82:701–708.CrossRefGoogle Scholar

Copyright information

© R.G. Landes Company 1997

Authors and Affiliations

  • Hanspeter Naegeli
    • 1
  1. 1.Institute of Pharmacology and ToxicologyUniversity of Zürich-TierspitalZürichSwitzerland

Personalised recommendations